Nebulized Budesonide Added to Standard Pediatric Emergency Department Treatment of Acute Asthma: A Randomized, Double-blind Trial
Academic Emergency Medicine, 07/18/2011
Upham BD et al.– For children 2 to 18 years of age treated in the emergency department (ED) for acute asthma, a single 2–mg dose of budesonide added to standard therapy did not improve asthma severity scores or other short–term ED–based outcomes.
The authors conducted a randomized, double-blind, placebo-controlled trial in a tertiary care, urban pediatric ED.
Patients 2 to 18 years of age with moderate to severe acute asthma were randomized to receive either a single 2-mg dose of budesonide inhalation suspension (BUD) or normal sterile saline (NSS) placebo, added to albuterol, ipratropium bromide (IB), and systemic corticosteroids (SCS).
The primary outcome was the difference in median asthma scores between treatment groups at 2 hours.
Secondary outcomes included differences in vital signs and hospitalization rates.
A total of 180 patients were enrolled.
Treatment groups had similar baseline demographics, asthma scores, and vital signs.
A total of 169 patients (88 BUD, 81 NSS) were assessed for the primary outcome.
No significant difference was found between groups in the change in median asthma score at 2 hours (BUD –3, NSS –3, p=0.64).
Vital signs at 2 hours were also similar between groups.
Fifty-six children (62%) were admitted to the hospital in the BUD group and 55 (62%) in the NSS group (difference 0%, 95% confidence interval [CI]=–14% to 14%).
Neither multivariate adjustment nor planned subgroup analysis by inhaled corticosteroids (ICS) use prior to the ED significantly altered the results.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.